Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p>
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| অন্যান্য লেখক: | , , , , , , , , , , , , , , , , , , , , |
| প্রকাশিত: |
2025
|
| বিষয়গুলি: | |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
| _version_ | 1849927633301667840 |
|---|---|
| author | Amir T. Fathi (15313195) |
| author2 | Haesook T. Kim (15313198) Robert J. Soiffer (15313201) Mark J. Levis (15313204) Shuli Li (15313207) Annette S. Kim (15117505) Zachariah DeFilipp (15313210) Areej El-Jawahri (15313213) Steve L. McAfee (15313216) Andrew M. Brunner (15313219) Philip C. Amrein (15313222) Alice S. Mims (11016414) Laura W. Knight (15313225) Devon Kelley (15313228) AJ S. Bottoms (15313231) Lindsey H. Perry (15313234) Jonathan L. Wahl (15313237) Jennifer Brock (15313240) Elayne Breton (15313243) Dylan M. Marchione (14935655) Vincent T. Ho (15313246) Yi-Bin Chen (15313249) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Amir T. Fathi (15313195) Haesook T. Kim (15313198) Robert J. Soiffer (15313201) Mark J. Levis (15313204) Shuli Li (15313207) Annette S. Kim (15117505) Zachariah DeFilipp (15313210) Areej El-Jawahri (15313213) Steve L. McAfee (15313216) Andrew M. Brunner (15313219) Philip C. Amrein (15313222) Alice S. Mims (11016414) Laura W. Knight (15313225) Devon Kelley (15313228) AJ S. Bottoms (15313231) Lindsey H. Perry (15313234) Jonathan L. Wahl (15313237) Jennifer Brock (15313240) Elayne Breton (15313243) Dylan M. Marchione (14935655) Vincent T. Ho (15313246) Yi-Bin Chen (15313249) |
| author_role | author |
| dc.creator.none.fl_str_mv | Amir T. Fathi (15313195) Haesook T. Kim (15313198) Robert J. Soiffer (15313201) Mark J. Levis (15313204) Shuli Li (15313207) Annette S. Kim (15117505) Zachariah DeFilipp (15313210) Areej El-Jawahri (15313213) Steve L. McAfee (15313216) Andrew M. Brunner (15313219) Philip C. Amrein (15313222) Alice S. Mims (11016414) Laura W. Knight (15313225) Devon Kelley (15313228) AJ S. Bottoms (15313231) Lindsey H. Perry (15313234) Jonathan L. Wahl (15313237) Jennifer Brock (15313240) Elayne Breton (15313243) Dylan M. Marchione (14935655) Vincent T. Ho (15313246) Yi-Bin Chen (15313249) |
| dc.date.none.fl_str_mv | 2025-11-25T13:06:51Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30707491 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplemental_Figure_1_from_Multicenter_Phase_I_Trial_of_Ivosidenib_as_Maintenance_Treatment_Following_Allogeneic_Hematopoietic_Cell_Transplantation_for_i_IDH1_i_-Mutated_Acute_Myeloid_Leukemia/30707491 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Hematological Cancers Leukemias Immunotherapy Stem cell transplantation |
| dc.title.none.fl_str_mv | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_5cd400cc59f9e87125415260a53886d0 |
| identifier_str_mv | 10.1158/1078-0432.30707491 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30707491 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid LeukemiaAmir T. Fathi (15313195)Haesook T. Kim (15313198)Robert J. Soiffer (15313201)Mark J. Levis (15313204)Shuli Li (15313207)Annette S. Kim (15117505)Zachariah DeFilipp (15313210)Areej El-Jawahri (15313213)Steve L. McAfee (15313216)Andrew M. Brunner (15313219)Philip C. Amrein (15313222)Alice S. Mims (11016414)Laura W. Knight (15313225)Devon Kelley (15313228)AJ S. Bottoms (15313231)Lindsey H. Perry (15313234)Jonathan L. Wahl (15313237)Jennifer Brock (15313240)Elayne Breton (15313243)Dylan M. Marchione (14935655)Vincent T. Ho (15313246)Yi-Bin Chen (15313249)CancerTherapeutic Research and DevelopmentImmuno-oncologyClinical Research and TrialsClinical Trial ResultsPhase I clinical trialsDrug TargetsOncoprotein & tumor suppressor drug targetsHematological CancersLeukemiasImmunotherapyStem cell transplantation<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p>2025-11-25T13:06:51ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30707491https://figshare.com/articles/figure/Supplemental_Figure_1_from_Multicenter_Phase_I_Trial_of_Ivosidenib_as_Maintenance_Treatment_Following_Allogeneic_Hematopoietic_Cell_Transplantation_for_i_IDH1_i_-Mutated_Acute_Myeloid_Leukemia/30707491CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307074912025-11-25T13:06:51Z |
| spellingShingle | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Amir T. Fathi (15313195) Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Hematological Cancers Leukemias Immunotherapy Stem cell transplantation |
| status_str | publishedVersion |
| title | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| title_full | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| title_fullStr | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| title_full_unstemmed | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| title_short | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| title_sort | Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia |
| topic | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Hematological Cancers Leukemias Immunotherapy Stem cell transplantation |